| 摘要 |
<p>The invention concerns the use of a nucleotide sequence derived from all or part of the genomic RNA 5' end of a type C retrovirus except for Friend murine leukaemia virus (FMLV) and Moloney murine leukaemia virus (MoMLV) as internal ribosome entry site or as element enabling or improving retrovirus vector packaging. The invention also concerns a vector comprising said nucleotide sequence, a viral particle generated from this vector, a cell comprising this vector or infected by the viral particle, their therapeutic use and a pharmaceutical composition containing them. The invention further concerns the use of a vector, a viral particle or a pharmaceutical composition for transfecting or infecting pluripotent stem cells.</p> |
